Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong
Kelly Dong obtained her PhD degree from McGill University, Canada. Kelly has nearly 25 years of multinational industry experience working for pharmaceutical companies and CROs in Canada, the UK and China. Her scientific expertise encompasses drug metabolism and pharmacokinetics (DMPK) in drug discov...
Gespeichert in:
| Veröffentlicht in: | Bioanalysis 2019-11, Vol.11 (22), p.2025-2026 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2026 |
|---|---|
| container_issue | 22 |
| container_start_page | 2025 |
| container_title | Bioanalysis |
| container_volume | 11 |
| creator | Dong, Kelly |
| description | Kelly Dong obtained her PhD degree from McGill University, Canada. Kelly has nearly 25 years of multinational industry experience working for pharmaceutical companies and CROs in Canada, the UK and China. Her scientific expertise encompasses drug metabolism and pharmacokinetics (DMPK) in drug discovery and regulated bioanalysis for preclinical and clinical development. After 20-year overseas experience, she joined GlaxoSmithKline R&D China in August 2009. She was the Director of DMPK for CNS drug discovery and Head of Bioanalysis, Immunogenicity and Biomarkers, overseeing more than 40 preclinical and clinical studies across different therapeutic areas. She joined United-Power Pharma as the Chief Executive Officer in February 2018. She is also a research fellow at the National Engineering Research Center of Protein Drugs. She is one of the founders and a steering committee member of China Bioanalysis Forum. She is also an active contributor to the scientific community, with numerous scientific publications, invited presentations and organizing scientific conferences.
This interview was conducted by Sankeetha Nadarajah, Managing Commissioning Editor of
. |
| doi_str_mv | 10.4155/bio-2019-0255 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2454634528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2454634528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-babfcbf16d380b996910e06a684b62a0d09f7cc9a66672f93d6ebdba02ba4a163</originalsourceid><addsrcrecordid>eNp1kL9OwzAQhy0EolXpyIosMQfsxHFiNlT-tKIIBpgt27m0rtqk2E6rvg3PwpORKqUbt9yd9N3vpA-hS0puGE3TW23rKCZURCRO0xPUp1maRZwKcXqcc9JDQ-8XpK0kzgUT56iXUM5SSlkfTd7B-TWYYDfgcV3hMAdcOFUGPBmNf75fKcGzxhaqMnCHVYVtFcBtLGzx1oY5foHlcocf6mp2gc5KtfQwPPQB-nx6_BiNo-nb82R0P41MwnmItNKl0SXlRZITLQQXlADhiudM81iRgogyM0YoznkWlyIpOOhCKxJrxRTlyQBdd7lrV3814INc1I2r2pcyZinjCUvjvKWijjKu9t5BKdfOrpTbSUrk3p1s3cm9O7l31_JXh9RGr6A40n-mWkB0QNmExoE3FlolstvaC2tsBf-E_wIK03zT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454634528</pqid></control><display><type>article</type><title>Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong</title><source>MEDLINE</source><source>PubMed Central</source><creator>Dong, Kelly</creator><creatorcontrib>Dong, Kelly</creatorcontrib><description>Kelly Dong obtained her PhD degree from McGill University, Canada. Kelly has nearly 25 years of multinational industry experience working for pharmaceutical companies and CROs in Canada, the UK and China. Her scientific expertise encompasses drug metabolism and pharmacokinetics (DMPK) in drug discovery and regulated bioanalysis for preclinical and clinical development. After 20-year overseas experience, she joined GlaxoSmithKline R&D China in August 2009. She was the Director of DMPK for CNS drug discovery and Head of Bioanalysis, Immunogenicity and Biomarkers, overseeing more than 40 preclinical and clinical studies across different therapeutic areas. She joined United-Power Pharma as the Chief Executive Officer in February 2018. She is also a research fellow at the National Engineering Research Center of Protein Drugs. She is one of the founders and a steering committee member of China Bioanalysis Forum. She is also an active contributor to the scientific community, with numerous scientific publications, invited presentations and organizing scientific conferences.
This interview was conducted by Sankeetha Nadarajah, Managing Commissioning Editor of
.</description><identifier>ISSN: 1757-6180</identifier><identifier>EISSN: 1757-6199</identifier><identifier>DOI: 10.4155/bio-2019-0255</identifier><identifier>PMID: 31645114</identifier><language>eng</language><publisher>England: Newlands Press Ltd</publisher><subject>Associations ; bioanalytical method validation ; Chemistry Techniques, Analytical ; China Bioanalysis Forum ; Drug discovery ; Drug Industry ; Drug metabolism ; global harmonization ; Guidelines as Topic ; ICH M10 feedback ; Immunogenicity ; International Agencies ; Laboratories ; Pharmaceutical industry ; Pharmacokinetics ; Protein engineering ; Reference Standards ; Regulatory agencies ; regulatory landscape ; Regulatory reform ; Social Control, Formal</subject><ispartof>Bioanalysis, 2019-11, Vol.11 (22), p.2025-2026</ispartof><rights>2019 Newlands Press</rights><rights>Copyright Newlands Press Nov 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31645114$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dong, Kelly</creatorcontrib><title>Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong</title><title>Bioanalysis</title><addtitle>Bioanalysis</addtitle><description>Kelly Dong obtained her PhD degree from McGill University, Canada. Kelly has nearly 25 years of multinational industry experience working for pharmaceutical companies and CROs in Canada, the UK and China. Her scientific expertise encompasses drug metabolism and pharmacokinetics (DMPK) in drug discovery and regulated bioanalysis for preclinical and clinical development. After 20-year overseas experience, she joined GlaxoSmithKline R&D China in August 2009. She was the Director of DMPK for CNS drug discovery and Head of Bioanalysis, Immunogenicity and Biomarkers, overseeing more than 40 preclinical and clinical studies across different therapeutic areas. She joined United-Power Pharma as the Chief Executive Officer in February 2018. She is also a research fellow at the National Engineering Research Center of Protein Drugs. She is one of the founders and a steering committee member of China Bioanalysis Forum. She is also an active contributor to the scientific community, with numerous scientific publications, invited presentations and organizing scientific conferences.
This interview was conducted by Sankeetha Nadarajah, Managing Commissioning Editor of
.</description><subject>Associations</subject><subject>bioanalytical method validation</subject><subject>Chemistry Techniques, Analytical</subject><subject>China Bioanalysis Forum</subject><subject>Drug discovery</subject><subject>Drug Industry</subject><subject>Drug metabolism</subject><subject>global harmonization</subject><subject>Guidelines as Topic</subject><subject>ICH M10 feedback</subject><subject>Immunogenicity</subject><subject>International Agencies</subject><subject>Laboratories</subject><subject>Pharmaceutical industry</subject><subject>Pharmacokinetics</subject><subject>Protein engineering</subject><subject>Reference Standards</subject><subject>Regulatory agencies</subject><subject>regulatory landscape</subject><subject>Regulatory reform</subject><subject>Social Control, Formal</subject><issn>1757-6180</issn><issn>1757-6199</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kL9OwzAQhy0EolXpyIosMQfsxHFiNlT-tKIIBpgt27m0rtqk2E6rvg3PwpORKqUbt9yd9N3vpA-hS0puGE3TW23rKCZURCRO0xPUp1maRZwKcXqcc9JDQ-8XpK0kzgUT56iXUM5SSlkfTd7B-TWYYDfgcV3hMAdcOFUGPBmNf75fKcGzxhaqMnCHVYVtFcBtLGzx1oY5foHlcocf6mp2gc5KtfQwPPQB-nx6_BiNo-nb82R0P41MwnmItNKl0SXlRZITLQQXlADhiudM81iRgogyM0YoznkWlyIpOOhCKxJrxRTlyQBdd7lrV3814INc1I2r2pcyZinjCUvjvKWijjKu9t5BKdfOrpTbSUrk3p1s3cm9O7l31_JXh9RGr6A40n-mWkB0QNmExoE3FlolstvaC2tsBf-E_wIK03zT</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Dong, Kelly</creator><general>Newlands Press Ltd</general><general>Newlands Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20191101</creationdate><title>Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong</title><author>Dong, Kelly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-babfcbf16d380b996910e06a684b62a0d09f7cc9a66672f93d6ebdba02ba4a163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Associations</topic><topic>bioanalytical method validation</topic><topic>Chemistry Techniques, Analytical</topic><topic>China Bioanalysis Forum</topic><topic>Drug discovery</topic><topic>Drug Industry</topic><topic>Drug metabolism</topic><topic>global harmonization</topic><topic>Guidelines as Topic</topic><topic>ICH M10 feedback</topic><topic>Immunogenicity</topic><topic>International Agencies</topic><topic>Laboratories</topic><topic>Pharmaceutical industry</topic><topic>Pharmacokinetics</topic><topic>Protein engineering</topic><topic>Reference Standards</topic><topic>Regulatory agencies</topic><topic>regulatory landscape</topic><topic>Regulatory reform</topic><topic>Social Control, Formal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dong, Kelly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Bioanalysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dong, Kelly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong</atitle><jtitle>Bioanalysis</jtitle><addtitle>Bioanalysis</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>11</volume><issue>22</issue><spage>2025</spage><epage>2026</epage><pages>2025-2026</pages><issn>1757-6180</issn><eissn>1757-6199</eissn><abstract>Kelly Dong obtained her PhD degree from McGill University, Canada. Kelly has nearly 25 years of multinational industry experience working for pharmaceutical companies and CROs in Canada, the UK and China. Her scientific expertise encompasses drug metabolism and pharmacokinetics (DMPK) in drug discovery and regulated bioanalysis for preclinical and clinical development. After 20-year overseas experience, she joined GlaxoSmithKline R&D China in August 2009. She was the Director of DMPK for CNS drug discovery and Head of Bioanalysis, Immunogenicity and Biomarkers, overseeing more than 40 preclinical and clinical studies across different therapeutic areas. She joined United-Power Pharma as the Chief Executive Officer in February 2018. She is also a research fellow at the National Engineering Research Center of Protein Drugs. She is one of the founders and a steering committee member of China Bioanalysis Forum. She is also an active contributor to the scientific community, with numerous scientific publications, invited presentations and organizing scientific conferences.
This interview was conducted by Sankeetha Nadarajah, Managing Commissioning Editor of
.</abstract><cop>England</cop><pub>Newlands Press Ltd</pub><pmid>31645114</pmid><doi>10.4155/bio-2019-0255</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-6180 |
| ispartof | Bioanalysis, 2019-11, Vol.11 (22), p.2025-2026 |
| issn | 1757-6180 1757-6199 |
| language | eng |
| recordid | cdi_proquest_journals_2454634528 |
| source | MEDLINE; PubMed Central |
| subjects | Associations bioanalytical method validation Chemistry Techniques, Analytical China Bioanalysis Forum Drug discovery Drug Industry Drug metabolism global harmonization Guidelines as Topic ICH M10 feedback Immunogenicity International Agencies Laboratories Pharmaceutical industry Pharmacokinetics Protein engineering Reference Standards Regulatory agencies regulatory landscape Regulatory reform Social Control, Formal |
| title | Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T17%3A47%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perspectives%20on%20the%20draft%20ICH%C2%A0M10%20guidance:%20an%20interview%20with%20Kelly%20Dong&rft.jtitle=Bioanalysis&rft.au=Dong,%20Kelly&rft.date=2019-11-01&rft.volume=11&rft.issue=22&rft.spage=2025&rft.epage=2026&rft.pages=2025-2026&rft.issn=1757-6180&rft.eissn=1757-6199&rft_id=info:doi/10.4155/bio-2019-0255&rft_dat=%3Cproquest_cross%3E2454634528%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454634528&rft_id=info:pmid/31645114&rfr_iscdi=true |